175 related articles for article (PubMed ID: 29368043)
1. Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study.
Hollis K; Proctor C; McBride D; Balp MM; McLeod L; Hunter S; Tian H; Khalil S; Maurer M
Am J Clin Dermatol; 2018 Apr; 19(2):267-274. PubMed ID: 29368043
[TBL] [Abstract][Full Text] [Related]
2. Comparison and interpretability of the available urticaria activity scores.
Hawro T; Ohanyan T; Schoepke N; Metz M; Peveling-Oberhag A; Staubach P; Maurer M; Weller K
Allergy; 2018 Jan; 73(1):251-255. PubMed ID: 28815631
[TBL] [Abstract][Full Text] [Related]
3. The Urticaria Activity Score-Validity, Reliability, and Responsiveness.
Hawro T; Ohanyan T; Schoepke N; Metz M; Peveling-Oberhag A; Staubach P; Maurer M; Weller K
J Allergy Clin Immunol Pract; 2018; 6(4):1185-1190.e1. PubMed ID: 29128337
[TBL] [Abstract][Full Text] [Related]
4. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria.
Stull D; McBride D; Tian H; Gimenez Arnau A; Maurer M; Marsland A; Balp MM; Khalil S; Grattan C
Br J Dermatol; 2017 Oct; 177(4):1093-1101. PubMed ID: 28295198
[TBL] [Abstract][Full Text] [Related]
5. Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study).
Jauregui I; Gimenez-Arnau A; Bartra J; Labrador-Horrillo M; de Frutos JO; Silvestre JF; Sastre J; Velasco M; Ferrer M; Ballesteros C; Valero A
Health Qual Life Outcomes; 2019 Jan; 17(1):23. PubMed ID: 30704532
[TBL] [Abstract][Full Text] [Related]
6. Validity and responsiveness of the Urticaria Activity and Impact Measure: A new patient-reported tool.
Maurer M; Mathias SD; Crosby RD; Rajput Y; Zazzali JL
Ann Allergy Asthma Immunol; 2018 Jun; 120(6):641-647. PubMed ID: 29567359
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
[TBL] [Abstract][Full Text] [Related]
8. Chronic Urticaria Biomarkers IL-6, ESR and CRP in Correlation with Disease Severity and Patient Quality of Life-A Pilot Study.
Kuna M; Štefanović M; Ladika Davidović B; Mandušić N; Birkić Belanović I; Lugović-Mihić L
Biomedicines; 2023 Aug; 11(8):. PubMed ID: 37626727
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab in chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response.
Nettis E; Cegolon L; Di Leo E; Lodi Rizzini F; Detoraki A; Canonica GW;
Ann Allergy Asthma Immunol; 2018 Oct; 121(4):474-478. PubMed ID: 29949781
[TBL] [Abstract][Full Text] [Related]
10. Serum Amyloid A as a Potential Biomarker for Disease Activity in Chronic Spontaneous Urticaria.
Carvallo A; Veleiro B; Sabaté-Brescó M; Baeza ML; Guilarte M; Herrera-Lasso V; Rodríguez-Garijo N; Diaz Donado C; Labrador-Horrillo M; Ferrer M
J Allergy Clin Immunol Pract; 2024 Jan; 12(1):195-200. PubMed ID: 37716523
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Jia HX; He YL
Am J Ther; 2020; 27(5):e455-e467. PubMed ID: 32427616
[TBL] [Abstract][Full Text] [Related]
12. Probiotic as an adjuvant therapy in chronic urticaria: a blinded randomized controlled clinical trial.
Atefi N; Fallahpour M; Sharifi S; Ghassemi M; Roohaninasab M; Goodarzi A
Eur Ann Allergy Clin Immunol; 2022 May; 54(3):123-130. PubMed ID: 33939347
[No Abstract] [Full Text] [Related]
13. The validity and reliability of the Thai-version of 5-D itch scale.
Tuchinda P; Kulthanan K; Chularojanamontri L; Rujitharanawong C; Subchookul C; Trakanwittayarak S
Asian Pac J Allergy Immunol; 2022 Sep; 40(3):254-262. PubMed ID: 32247306
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience.
Nettis E; Cegolon L; Di Leo E; Canonica WG; Detoraki A;
Ann Allergy Asthma Immunol; 2018 Mar; 120(3):318-323. PubMed ID: 29508719
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.
Mathias SD; Crosby RD; Zazzali JL; Maurer M; Saini SS
Ann Allergy Asthma Immunol; 2012 Jan; 108(1):20-24. PubMed ID: 22192960
[TBL] [Abstract][Full Text] [Related]
16. The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study).
Lacour JP; Khemis A; Giordano-Labadie F; Martin L; Staumont-Salle D; Hacard F; Tian H; McBride D; Hollis K; Hunter S; Martin L; Lamirand A; Le Guen S; Balp MM; Berard F
Eur J Dermatol; 2018 Dec; 28(6):795-802. PubMed ID: 30698148
[TBL] [Abstract][Full Text] [Related]
17. The Arabic Urticaria Activity Score and Chronic Urticaria Quality of Life Questionnaire: validation and correlations.
Tawil S; Irani C; Kfoury R; Salameh P; Baiardini I; Weller K; Maurer M; Ezzedine K
Int J Dermatol; 2020 Aug; 59(8):893-901. PubMed ID: 32638368
[TBL] [Abstract][Full Text] [Related]
18. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
Jain V; Giménez-Arnau A; Hayama K; Reich A; Carr W; Tillinghast J; Dahale S; Lheritier K; Walsh P; Zharkov A; Hugot S; Haemmerle S
J Allergy Clin Immunol; 2024 Feb; 153(2):479-486.e4. PubMed ID: 37866460
[TBL] [Abstract][Full Text] [Related]
19. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results.
Kolkhir P; Laires PA; Salameh P; Asero R; Bizjak M; Košnik M; Dissemond J; van Doorn M; Hawro T; Kasperska-Zajac A; Zajac M; Kocatürk E; Peter J; Parisi CAS; Ritchie CA; Kulthanan K; Tuchinda P; Fomina D; Kovalkova E; Khoshkhui M; Kouzegaran S; Papapostolou N; Du-Thanh A; Kamegashira A; Meshkova R; Vitchuk A; Bauer A; Grattan C; Staubach P; Bouillet L; Giménez-Arnau AM; Maurer M; Weller K
J Allergy Clin Immunol Pract; 2023 Feb; 11(2):610-620.e5. PubMed ID: 36481420
[TBL] [Abstract][Full Text] [Related]
20. The minimal important difference for measures of urticaria disease activity: Updated findings.
Mathias SD; Crosby RD; Rosén KE; Zazzali JL
Allergy Asthma Proc; 2015; 36(5):394-8. PubMed ID: 26314821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
